Bonn

• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive … Ended recruitment
  2023-503568-18-00 5 2021-04-13 Early human epidermal growth factor receptor 2 (HER2) positive breast
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 … Ended recruitment
  2023-505964-13-00 5 2021-03-09 Hemophilia A
• A Phase II clinical trial comparing the efficacy of RO7198457 versus watchful waiting in patients with ctDNA positive, resected Stage II (hi … Ended recruitment
  2023-509516-28-00 4 2021-02-22 Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III col
• A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended recruitment
  2024-514502-31-00 5 2021-01-11 Prurigo Nodularis
• Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended recruitment
  2024-514404-13-00 5 2020-10-01 Atopic Dermatitis
• A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi … Ended recruitment
  2023-509242-35-00 5 2020-07-23 HR+/HER2- early breast cancer
• RACE-trial: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of t … Ended recruitment
  2024-516271-32-00 5 2020-06-03 Adenocarcinoma of the gastroesophageal junction (AEG type I-III)
• A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand s … Ended recruitment
  2024-512682-14-00 4 2020-04-06 Non-resectable hepatocellular carcinoma (HCC)
• A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemop … Ended recruitment
  2022-502844-11-00 5 2020-01-29 severe to moderately severe hemophilia B (FIX:C ≤ 2%)
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• Copanlisib and Rituximab in Marginal Zone Lymphoma Patients - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (COUP-1) Ended recruitment
  2022-500674-34-00 4 2019-11-04 Marginal Zone Lymphoma
• Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch … Ended recruitment
  2022-502354-14-00 5 2019-10-28 Completely resected Stage IIb/c melanoma
• Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by strok … Ended recruitment
  2023-505810-12-00 5 2019-09-03 Lower limb spasticity
• Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno … Ended recruitment
  2023-503670-21-00 5 2019-08-28 Patients with newly diagnosed AML and intermediate- or adverse-risk ge
• Comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AML Ended recruitment
  2024-515375-35-00 4 2019-08-26 Untreated patients with higher risk MDS and oligoblastic AML eligible
• Study for patients with Primary Hyperoxaluria to evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection Ended recruitment
  2024-512260-54-00 5 2019-08-20 Primary Hyperoxaluria
• Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours Ended recruitment
  2023-507582-25-00 5 2019-08-02 Malignant Extracranial Germ Cell Tumours (MGCT)
• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto … Ended recruitment
  2023-504932-16-00 5 2019-06-04 Muscle Invasive Bladder Cancer
• EffisayilTM ON: A study to test long-term treatment with spesolimab in people with generalized pustular psoriasis who took part in a previou … Ended recruitment
  2023-509216-28-00 4 2019-05-27 Generalized Pustular Psoriasis
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma … Ended recruitment
  2022-502937-24-00 5 2019-01-02 Atopic Dermatitis
• Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended recruitment
  2023-506921-12-00 5 2018-12-27 ER+/HER2- Breast Cancer
• A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio … Ended recruitment
  2024-513464-26-00 5 2018-10-18 Multiple Myeloma

Showing 313–336 of 440 trials